Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$205.26 USD

205.26
632,500

+0.95 (0.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 11% (28 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zubia Masood headshot

Should You Buy, Hold or Sell HCA Healthcare Stock After Q3 Earnings?

by Zubia Masood

HCA is poised to benefit from volume growth and expansion initiatives.

Universal Health Q3 Earnings Miss on Elevated Operating Costs

by Zacks Equity Research

UHS' Q3 results suffer from rising operating costs in salaries, wages and benefits, and supplies, impacting profitability. Nevertheless, strong revenue growth and increased admissions partly offset the downside.

Compared to Estimates, Universal Health Services (UHS) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Universal Health Services (UHS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Universal Health Services (UHS) Lags Q3 Earnings Estimates

by Zacks Equity Research

Universal Health Services (UHS) delivered earnings and revenue surprises of -1.07% and 1.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Are Investors Undervaluing Universal Health Services (UHS) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

by Zacks Equity Research

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zubia Masood headshot

HCA Healthcare Pre-Q3 Earnings: Healthy Buy or a Diagnosis to Wait?

by Zubia Masood

HCA's third-quarter earnings are likely to benefit from improved admissions, capacity additions and payer mix, partially offset by rising operating expenses.

Debasmita Chatterjee headshot

Analyzing Universal Health Pre-Q3 Earnings: Time to Buy the Stock?

by Debasmita Chatterjee

UHS' Q3 results are likely to be driven by rising admissions in acute care hospitals and higher revenue per adjusted patient day in behavioral health hospitals.

Curious about Universal Health Services (UHS) Q3 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Universal Health Services (UHS) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Universal Health Services (UHS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Universal Health Services (UHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Community Health Teams Up With Denim to Scale Conversational AI

by Zacks Equity Research

With this move, CYH intends to streamline agent workload, which can result in more savings for the company.

Debasmita Chatterjee headshot

Does Universal Health's Low P/E Ratio Signal a Suitable Entry Point?

by Debasmita Chatterjee

UHS rides on increased patient volumes. It can effectively cater to its patients through its extensive treatment network.

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock.

Here's Why You Should Add Masimo Stock to Your Portfolio Now

by Zacks Equity Research

MASI's R&D activities raise optimism about the stock.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

by Zacks Equity Research

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Is Universal Health Services (UHS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why Universal Health Services (UHS) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise

by Zacks Equity Research

AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.

Reasons to Add Baxter International Stock to Your Portfolio Now

by Zacks Equity Research

BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Here's Why You Should Retain Merit Medical Stock in Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Reasons to Add Avanos Medical Stock in Your Portfolio Now

by Zacks Equity Research

AVNS's strong product line and focus on R&D raise optimism about the stock.

Ensign Expands Presence in Nebraska With Two Acquisitions

by Zacks Equity Research

ENSG's acquisitions in Nebraska are expected to strengthen its portfolio in the region, leading to improved skilled services revenues in the future.

Brookdale Bets Big With $610M Acquisitions Amid Debt Refinancing

by Zacks Equity Research

These acquisitions will add 2,789 units to BKD's owned portfolio and enable it to increase its owned units to 66% of its total units.

FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives

by Zacks Equity Research

Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.